Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* Female and male patients aged ≥18 and ≤ 90 years~* Two consecutive i-STAT potassium values, measured 60-minutes (± 10 minutes) apart, both ≥ 5.1 mmol/l and measured within 1 day of the first ZS dose on 48-hour open-label initial phase Day 1~* Ability to have repeated blood draws or effective venous catheterization~* Female patients must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception for the duration of the study and for 3 months after the last dose of ZS/matching placebo to prevent pregnancy.~Exclusion Criteria:~* Involvement in the planning and/or conduct of the study~* Participation in another clinical study with an investigational product during the last 3 months~* Pseudohyperkalemia signs and symptoms~* Patients treated with lactulose, xifaxan (rifaximin) or other non-absorbed antibiotics for hyperammonemia within 7 days prior to the first dose of study drug~* Patients treated with resins,calcium acetate,calcium carbonate, or lanthanum carbonate,within 7 days prior to the first dose of study drug~* Patients with a life expectancy of less than 3 months~* Patients who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the subjects' tasks associated with the protocol~* Female patients who are pregnant, lactating, or planning to become pregnant~* Patients with diabetic ketoacidosis~* Presence of any condition which, in the opinion of the investigator, places the patient at undue risk or potentially jeopardizes the quality of the data to be generated~* Known hypersensitivity or previous anaphylaxis to ZS or to components thereof~* Patients with cardiac arrhythmias that require immediate treatment~* Patients on dialysis~* Patients who are blood donors should not donate blood during the study and for 3 months following their last dose of ZS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Sodium Zirconium Cyclosilicate (ZS) 5g (Type: EXPERIMENTAL): Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
- Sodium Zirconium Cyclosilicate (ZS) 10g (Type: EXPERIMENTAL): Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
- Placebo (Type: PLACEBO_COMPARATOR): Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).